What is ImmuCell?
ImmuCell Corporation (Nasdaq: ICCC) operates at the intersection of biotechnology and agricultural science, focusing on the development of scientifically validated solutions for the dairy and beef cattle industries. The company is best known for its flagship product, First Defense, which provides immediate immunity to newborn calves, a critical intervention for herd health management. Furthermore, ImmuCell is currently in the advanced stages of bringing Re-Tain to market, a proprietary treatment for subclinical mastitis that eliminates the need for milk discard, offering a significant value proposition to dairy producers seeking alternatives to traditional antibiotic protocols. Through these innovations, ImmuCell addresses essential productivity challenges in the livestock sector, positioning itself as a key player in the global animal health market.
How much funding has ImmuCell raised?
ImmuCell has raised a total of $32.6M across 8 funding rounds:
Stock Offering
$5.9M
Share Placement
$3.5M
Multiple Rounds
$10.3M
Stock Offering
$8.3M
Debt
$350K
Share Placement
$4.3M
Stock Issuance/Offering (2016): $5.9M with participation from Undisclosed
Share Placement (2016): $3.5M led by Undisclosed
Debt (2017): $6.5M supported by TD Bank N.A
Private Equity (2017): $1.1M featuring Sandra F. Pessin and Brian L. Pessin
Stock Issuance/Offering (2017): $2.7M backed by Craig-Hallum Capital Group
Stock Issuance/Offering (2019): $8.3M with participation from Craig-Hallum Capital Group
Debt (2020): $350K led by PPP
Share Placement (2021): $4.3M, investors not publicly disclosed
Key Investors in ImmuCell
Craig-Hallum Capital Group
A full-service investment banking firm that provides research, sales, and trading services, often acting as a strategic partner for growth-oriented companies.
TD Bank N.A
A major financial institution providing comprehensive banking and credit solutions to support corporate capital requirements and debt financing needs.
Sandra F. Pessin
An individual investor who has participated in private equity financing rounds to support the company's long-term development goals.
What's next for ImmuCell?
With the recent capital deployment, ImmuCell is strategically positioned to accelerate the commercial rollout of its late-stage pipeline assets. The focus remains on scaling the manufacturing and distribution capabilities required to meet the anticipated demand for Re-Tain, while simultaneously expanding the market penetration of its existing immunity-focused product portfolio. Investors are closely monitoring the company's ability to navigate regulatory milestones and achieve widespread adoption among large-scale dairy operations. As the firm leverages this latest financing, the primary objective is to transition these scientific advancements into sustainable revenue streams, thereby enhancing shareholder value and reinforcing its leadership in the bovine health space. The company's trajectory suggests a continued emphasis on operational efficiency and market-driven innovation to sustain its growth momentum.
See full ImmuCell company page
